Drug Type mRNA encoding bispecific antibody, Bispecific T-cell Engager (BiTE), Liposomal Drug |
Synonyms- |
Action inhibitors, stimulants |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FCRL5 inhibitors(Fc receptor-like protein 5 inhibitors) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | United States | 09 Dec 2024 |